Details of the Drug Reposition

General Information of This Drug (ID: DMQIBZD)

Drug Name
Silmitasertib   DMQIBZD
Synonyms CX-4945; CX4945; CX-4945 (Silmitasertib); CX 4945; UNII-C6RWP0N0L2; W-204393
Therapeutic Class
Antiviral Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Cholangiocarcinoma DIS71F6X 2C12.10 Phase 1/2 [1]
------------------------------------------------------------------------------------
1 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Investigative [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT02128282) Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma. U.S. National Institutes of Health.
2 News report, company report or official report of Senhwa Biosciences, Inc. Senhwa Biosciences Silmitasertib Named as Potential COVID-19 Therapy. 2020 March 31.